Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 9, 2017updated 22 Nov 2018 11:24am

EnteroMedics publishes positive data from study of vBloc in diabetes patients

Medical devices firm EnteroMedics has published positive three-year data from its VBLOC DM2 study of vBloc neurometabolic therapy in obese patients with Type 2 diabetes, in the Journal of Diabetes and Obesity.

Medical devices firm EnteroMedics has published positive three-year data from its VBLOC DM2 study of vBloc neurometabolic therapy in obese patients with Type 2 diabetes, in the Journal of Diabetes and Obesity.

vBloc neurometabolic therapy is designed to employ vBloc system, a pacemaker-like device, to intermittently block the vagus nerves using high-frequency, low-energy electrical impulses.

The international, open-label, prospective, multi-centre DM2 study evaluated the safety and efficacy of vBloc therapy in 28 diabetic patients with obesity.

"The data provides additional evidence of the benefit that vBloc therapy can offer to patients battling obesity and Type 2 diabetes."

EnteroMedics president and chief executive officer Dan Gladney said: "We are encouraged by the strong three year results seen in the VBLOC DM2 study, as the data provides additional evidence of the benefit that vBloc therapy can offer to patients battling obesity and Type 2 diabetes.

"Obesity and Type 2 diabetes are two of the most serious societal health concerns throughout the world today, and innovative treatments like vBloc therapy have the potential to stem the tide against these dangerous and debilitating conditions."

The study determined the average percentage excess weight loss (EWL), HbA1c (blood sugar), fasting plasma glucose (FPG, blood sugar) and blood pressure after activation of the device.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

The data indicated no deaths, unanticipated adverse device effects, or life-threatening complications over the three year period.

The firm has secured the US Food and Drug Administration approval and CE mark for its vBloc system.

The vBloc therapy is approved for use in aiding weight loss in people aged 18 years and above, who are obese with a related health condition such as Type 2 diabetes, high blood pressure, high cholesterol levels or obstructive sleep apnea.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU